OIPE JC13
OCT 30 2003
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet	1	of	6

COMPLETE IF KNOWN	
Application Number	10/679,999
Confirmation Number	
Filing Date	October 6, 2003
First Named Inventor	MANN, Michael *et al.*
Group Art Unit	1644
Examiner Name	HUYNH, PN
Attorney Docket No.	54113.8002.US02

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent or Application NUMBER	Kind Code (if known)	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
PNH	A1	4,179,337		DAVIS, *et al.*	12/18/79	
	A2	4,925,673		STEINER, *et al.*	05/15/90	
	A3	5,013,556		WOODLE, *et al.*	05/07/91	
	A4	5,073,627		CURTIS, *et al.*	12/17/91	
	A5	5,098,833		LASKY, *et al.*	03/24/92	
	A6	5,116,964		CAPON, *et al.*	05/26/92	
	A7	5,169,318		LEVY, Guy	12/08/92	
	A8	5,225,538		CAPON, *et al.*	07/06/93	
	A9	5,284,656		PLATZ, *et al.*	02/08/94	
	A0	5,349,053		LANDOLFI, *et al.*	09/20/94	
	A11	5,428,130		CAPON, *et al.*	06/27/95	
	A12	5,447,851		BEUTLER, *et al.*	09/05/95	
	A13	5,455,165		CAPON, *et al.*	10/13/95	
	A14	5,480,981		CURTIS, *et al.*	12/17/95	
	A15	5,514,582		CAPON, *et al.*	05/07/96	
	A16	*5,594,101		BECKER, *et al.*	03/03/95	
	A17	5,594,104		BASINSKI, *et al.*	01/14/97	
	A18	5,646,040		KLEYN, *et al.*	07/08/97	
	A19	5,670,625		BAUM, *et al.*	09/23/97	
	A20	5,714,147		CAPON, *et al.*	02/03/98	
	A21	5,739,277		PRESTA, *et al.*	04/14/98	
	A22	5,935,810		FRIEDMAN, *et al.*	08/10/99	
	A23	6,001,968		FRIEDMAN, *et al.*	12/14/99	
	A24	*6,025,325		CAMPFIELD, *et al.*	02/15/00	
✓	A25	*6,048,837		FRIEDMAN, *et al.*	04/11/00	

EXAMINER	DATE CONSIDERED
	10/18/04

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

OIPE JC17 OCT 30 2003 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet	2	of	6

COMPLETE IF KNOWN	
Application Number	10/679,999
Confirmation Number	
Filing Date	October 6, 2003
First Named Inventor	MANN, Michael *et al.*
Group Art Unit	1644
Examiner Name	Huynh, P.N.
Attorney Docket No.	54113.8002.US02

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Patent or Application: Office	NUMBER	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
PNH	B1		EP 306673			03/15/89		
	B2		EP 362999			04/11/90		
	B3		EP 401384			12/22/89		
	B4		EP 417563			03/20/91		
	B5		EP 464533			01/08/92		
	B6		WO 89/10932			11/16/89		
	B7		WO 91/11111			08/08/91		
	B8		*WO 92/13559			08/20/92		
	B9		WO 94/06476			03/31/94		
	B10		WO 96/03141			02/08/96		
	B11		WO 96/04388			02/15/96		
	B12		WO 96/05309			02/22/96		
	B13		WO 96/18412			06/20/96		
	B14		WO 96/22308			07/25/96		
	B15		WO 96/31526			10/10/96		
	B16		WO 97/00319			01/03/97		
	B17		WO 97/18833			05/29/97		
	B18		WO 97/24137			07/10/97		
	B19		WO 97/24440			07/10/97		
	B20		WO 98/28427			07/02/98		
	B21		WO 98/46257			10/22/98		
	B22		WO 99/02711			01/21/99		
√	B23		WO 99/22764			05/14/99		

EXAMINER	DATE CONSIDERED
	10/18/04

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

OIPE JC17 OCT 30 2003 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet	3	of	6

COMPLETE IF KNOWN	
Application Number	10/679,999
Confirmation Number	
Filing Date	October 6, 2003
First Named Inventor	MANN, Michael *et al.*
Group Art Unit	1644
Examiner Name	Huynh PJ
Attorney Docket No.	54113.8002.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
PJH	C1	ABUCHOWSKI, A. *et al.*, "Soluble Polymer-Enzyme Adducts," *Enzymes as Drugs* (J.S. Holcerberg and J. Roberts, eds.) 367-383 (1981).	
	C2	ADJEI, *et al.*, *Int'l. J. of Pharm.*, 61:135-144 (1990).	
	C3	ADJEI, *et al.*, *Pharm. Res.*, 7(6):565-569 (1990).	
	C4	ASHKENAZI, *et al.*, *A Companion to Methods in Enzymology*, 8:104-115 (1995).	
	C5	ASHKENAZI, A. *et al.*, "Protection Against Edotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin," *PNAS USA*, 88:10535-39 (1991).	
	C6	BACHMANN, *et al.*, *Bacteriol. Rev.*, 40:116-167 (1976).	
	C7	BARINAGA, M. "'Obese' Protein Slims Mice," *Science*, 269:475-476 (1995).	
	C8	BENNETT, B. *et al.*, "Estracellular Domain-IGG Fusion Proteins for Three Human Natriuretic Peptide Receptors," *J. BioChem.* 266:(34) 23060-67 (1991).	
	C9	BRAQUET, *et al.*, *J. Cardiovascular Pharm.* 13(Supp. 5):S143-S146 (1989).	
	C10	CAMPFIELD, L.A., *et al.*, "Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Liking Adiposity and Central Neural Networks," *Science*, 269:54-549 (1995).	
	C11	CAPON, D., *et al.*, "Designing CD4 Immunoadhesins for AIDS Therapy," *Nature*, 337:525-531 (February 9, 1989).	
	C12	DEBS, *et al.*, *J. Immun.*, 140(10):3482-3488 (1988).	
	C13	*DEVOS, R. *et al.*, "OB Protein Binds Specifically to the Choroid Plexus of Mice and Rats," *Proc. Natl. Acad. Sci. USA*, 93:5668-5673 (May 1996).	
↓	C14	ELLISON, *et al.*, "The Nucleotide Sequence of a Human Immunoglobulin Cγ1 Gene," *Nucleic Acids Research*, 10(13):4071-4079 (1982).	

EXAMINER	DATE CONSIDERED
P. Huynh	10/18/04

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

OIPE JC17 OCT 30 2003 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use several sheets if necessary)

Sheet	4	of	6

COMPLETE IF KNOWN	
Application Number	10/679,999
Confirmation Number	
Filing Date	October 6, 2003
First Named Inventor	MANN, Michael *et al.*
Group Art Unit	1644
Examiner Name	Huynh, PN
Attorney Docket No.	54113.8002.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
PNH	C15	FISHER,C., *et al.*, "Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein," *N. Engl. J. Med.*, 334:1697-17022 (1996).	
	C16	FRANCIS, *Focus on Growth Factors*, 3:4-10 (1992).	
	C17	HAAK-FRENDSCHO, M. *et al.*, "Inhibitin of Interferon-γ by an Interferon-γ Receptor Immunoadhesin," *Immunology*, 79:1-6 (1993).	
	C18	HALAAS, *et al.*, "Weight-Reducing Effects of the Plasma Protein Encoded by the *Obese* Gene," *Science*, 269:543-546 (1995).	
	C19	HARVEY, *et al.*, *Remington's Pharmaceutical Sciences*, 18th Ed., (Mack Publishing Co., Easton, PA, ed. Gennaro 1990), p. 948-1001.	
	C20	HARVILL, E. *et al.*, "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcγRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," *Immunotechnology*, 1:95-105 (1995).	
	C21	HO, S.N. *et al.*, "Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction," *Gene*, 77:51-59 (1989).	
	C22	HOLLENBAUGH, *et al.*, *Current Protocols in Immunology*, Supp. 4:10.19.1-10.19.11 (1992).	
	C23	HUBBARD, *et al.*, *Annals of Internal Medicine*, 111(3):206-212 (1989).	
	C24	IMAGAWA, K. *et al.*, "Structure-Function Studies of Human Leptin," *J. Biological Chem.*, 273(52):35245-49 (1998).	
	C25	LESHNER, *et al.*, *Physiology and Behavior*, 9:281-282 (1972).	
	C26	MacDONALD, *et al.*, *Methods in Enzymology*, 152:219-227 (1987).	
✓	C27	MALIK, F., *et al.*, "Polyethylen Glycol (PEG)-modifided Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity," *Exp. Hematol.*, 20:1028-1035 (1992).	

EXAMINER	DATE CONSIDERED
P N. H	10/18/04

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

OIPE
OCT 30 2003
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Form PTO-1449 (Modified) Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/679,999
				Confirmation Number	
				Filing Date	October 6, 2003
				First Named Inventor	MANN, Michael *et al.*
				Group Art Unit	1644
				Examiner Name	Huynh, P.D.
SHEET	5	of	6	Attorney Docket No.	54113.8002.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
PNH	C28	MARK, M. *et al.*, "Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins," *J. Bio Chem.*, 267:(36) 26166-71 (1992).	
	C29	MARSHALL, *Modern Pharmaceutics* (Marcel Dekker, Inc., NY, eds. Banker and Rhodes 1979) p. 359-427.	
	C30	MURAKAMI, T., *et al.*, "Cloning of Rat *Obese* cDNA and Its Expression in Obese Rats," *Biochem. Biophys. Res. Comm.*, 209(3):944-952 (1995).	
	C31	NEWMARK, *et al.*, *J. Appl. Biochem.* 4:185-189 (1982).	
	C32	*NGO, J.T., *et al.*, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," *The Protein Folding Problem and Tertiary Structure Prediction*, Chapter 14, Birkhauser, Boston p. 492-495 (1994).	
	C33	OESWEIN, *et al.*, "Aerosolization of Proteins," *Proceedings of Symposium on Respiratory Drug Delivery II*, Keystone, CO, March 1990.	
	C34	PELLEYMOUNTER, M.A., *et al.*, "Effects of the *Obese* Gene Product on Body Weight Regulation in *ob/ob* Mice," *Science*, 269:540-543 (1995).	
	C35	PRESCOTT, *et al.*, *Microbiology* (1990, Wm. C. Brown Publ., Dubuque, IA 52001) p. 599-602.	
	C36	*Remington's Pharmaceutical Sciences*, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) p. 1435-1712 (TABLE OF CONTENTS PROVIDED)	
	C37	*Remington's Pharmaceutical Sciences*, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) Chapter 89 (TABLE OF CONTENTS PROVIDED)	
	C38	SAMBROOK, *et al.*, *Molecular Cloning: A Laboratory Manual*, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (TABLE OF CONTENTS PROVIDED)	
	C39	SHIN, *et al.*, *Intern. Rev. Immunol.*, 10:177-186 (1993).	
✓	C40	SMITH, *et al.*, *J. Clin. Invest.*, 84:1145-1154 (1989).	

EXAMINER	DATE CONSIDERED
	10/18/04

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

OIPE JC13 OCT 30 2003 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/679,999
				Confirmation Number	
				Filing Date	October 6, 2003
				First Named Inventor	MANN, Michael *et al.*
				Group Art Unit	1644
				Examiner Name	Haywil, PAL
Sheet	6	of	6	Attorney Docket No.	54113.8002.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
PNK	C41	STEPHENS, T., *et al.*, "Life Without Neuropeptide Y," *Nature*, 377:530-532 (1995).	
	C42	*STRYER, L., *et al.*, *Biochemistry*, Third Edition, W H Freeman Company, New York, p. 31-33 (1998).	
	C43	SUSSMAN, *et al.*, *C.R. Acad. Sci.*, 254(8):1517-1519 (1962).	
	C44	VAN ZEE, K. *et al.*, "Protection Against Lethal *Escherichia coli* Bacteremia in Baboons (*Papio anubis*) by Pretreatment with a 55-kDa TNF Receptor (CD120a)-Ig Fusion Protein, Ro 45-2081," *J. Immunology*, 156:2221-2230 (1996).	
	C45	*VERMA, I. *et al.*, "Gene-Therapy—Promises, Problems, and Prospects," *Nature*, 389:239-242 (September 18, 1997).	
	C46	ZHANG, *et al.*, **Correction** at *Nature*, 374:479 (1995).	
	C47	ZHANG, Y., *et al.*, "Positional Cloning of the Mouse *Obese* Gene and its Human Homologue," *Nature*, 372:425-432 (1994).	
V	C48	ZHENG, X. *et al.*, "Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharide-Induced Septic Shock and Allogeneic Islet Transplantation," *The Journal of Immunology*, 154:5590-5600 (1995).	

EXAMINER	DATE CONSIDERED
	10/18/04

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).